Key result
Acute supplementation with 300 mg of EGCG significantly improved brachial artery flow-mediated dilation from 7.1% to 8.6% at two hours (P=0.01) in patients with coronary artery disease.
Why the study?
Does EGCG supplementation improve endothelial function in patients with coronary artery disease?
RCT (n=42)
double blind
randomized
Does EGCG supplementation improve endothelial function in patients with coronary artery disease?
p-value: p=0.01
Acute EGCG supplementation significantly improves endothelial function in patients with coronary artery disease, though the effect is not sustained 14 hours after a two-week regimen.
Acute EGCG improves endothelial function in CAD; extends acute endothelial data but leaves long-term durability open.
BACKGROUND: Epidemiological studies demonstrate an inverse relation between dietary flavonoid intake and cardiovascular risk. Recent studies with flavonoid-containing beverages suggest that the benefits of these nutrients may relate, in part, to improved endothelial function. OBJECTIVE: We hypothesized that dietary supplementation with epigallocatechin gallate (EGCG), a major catechin in tea, would improve endothelial function in humans. DESIGN: We examined the effects of EGCG on endothelial function in a double blind, placebo-controlled, crossover design study. We measured brachial artery flow-mediated dilation by vascular ultrasound at six time points: prior to treatment with EGCG or placebo, two hours after an initial dose of EGCG (300 mg) or placebo, and after two weeks of treatment with EGCG (150 mg twice daily) or placebo. The order of treatments (EGCG or placebo) was randomized and there was a one-week washout period between treatments. RESULTS: A total of 42 subjects completed the study, and brachial artery flow-mediated dilation improved from 7.1 +/- 4.1 to 8.6 +/- 4.7% two hours after the first dose of 300 mg of EGCG (P = 0.01), but was similar to baseline (7.8 +/- 4.2%, P = 0.12) after two weeks of treatment with the final measurements made approximately 14 hours after the last dose. Placebo treatment had no significant effect, and there were no changes in reactive hyperemia or the response to sublingual nitroglycerin. The changes in vascular function paralleled plasma EGCG concentrations, which increased from 2.6 +/- 10.9 to 92.8 +/- 78.7 ng/ml after acute EGCG (P < 0.001), but were unchanged from baseline after two weeks of treatment (3.4 +/- 13.1 ng/ml). CONCLUSION: EGCG acutely improves endothelial function in humans with coronary artery disease, and may account for a portion of the beneficial effects of flavonoid-rich food on endothelial function.
No takes yet. Share an insight, caveat, or question.
Widlansky et al. (2007) conducted an RCT in coronary artery disease (n=42). epigallocatechin gallate (EGCG) vs. placebo was evaluated on brachial artery flow-mediated dilation (p=0.01). Acute supplementation with 300 mg of EGCG significantly improved brachial artery flow-mediated dilation from 7.1% to 8.6% at two hours (P=0.01) in patients with coronary artery disease.